To develop standardized dissolution method for inhalation formulations • To adapt a USP2 dissolution aparatus for high throughput analysis
OBJECTIVES •
To develop standardized dissolution method for inhalation formulations • To adapt a USP2 dissolution aparatus for high throughput analysis
• To validate an optimized in vitro dissolution method using newly manufactured membrane holder • To study the broad applicability of this method to a wide range of inhaled pharmaceutical products
INTRODUCTION
Standardized dissolution test methods allow comparisons between various pharmaceutical dosage forms to be conducted in vitro. A predictive estimates of in vivo behavior may also be established.
While there are many standardized dissolution test methods for solid dosage forms such as tablets and capsules, there is no applicable standardized method to estimate the dissolution behavior for inhaled pharmaceutical formulations.
For inhalation products, only a fraction of the API emitted from standard delivery devices is usually delivered to target site, due to the fine particle size distribution for most inhaler products (1) . Thus, an ideal dissolution test procedure for inhalation formulations would involve particle classification followed by an evaluation of the dissolution behavior of those sorted drug particles that may deposit at various sites in the respiratory tract. However, most existing dissolution procedures on powders have been performed with no aerodynamic classification due to the existing experimental difficulties in dose collection (2) (3) (4) . • The PulmicortFlexhaler TM device, or the Ventolin® HFA device were fired into the NGI.
MATERIALS • Active pharmaceutical ingredients (APIs) & excipients
• Following actuation, the dose collection body was removed from the quick release collection plate.
• A pre-soaked membrane was placed onto the top and sealed in place with the top part of the new membrane holder.
• The sealed membrane holder was then placed into each dissolution vessel containing 300 mL of dissolution media.
Dissolution Test CONCLUSION
A new easy to use dissolution membrane holder for evaluating the in vitro dissolution behavior of inhalation formulations was desi gned. The dissolution rates of commercially available drug formulations were successfully estimated by analyzing the amount of drug released from this attachment for the NGI.
This dissolution method may be used for a quali ty control studies for various dry powder inhalers, in particular, the in vitro dissolution profiles of drug may provide an estimate of its dispersi on characteristi cs which directly relate to the device or aerosol performances.
Dose Collection for Dissolution Study
• Aerodynamic separation study • Thicker, larger and more compressed diffusion layer were created as an actuation time increases • Multi-layer powder bed is not appropriate for dissolution study because of dry portion inside the powder bed (for hydrophobic APIs) • Ideally, the device needs to be actuated one time to obtain well dispersed particles in an approximately single layer • The release amount of budesonide show significant differences • Variability in release rate increases as diffusion layer increases • Early time points (0, 5 and 10 minutes) are very useful 
